Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial Evaluating the VASCADE MVP System for Multi-Vessel Closure Following Electrophysiology Procedures

SANTA CLARA, Calif.–(BUSINESS WIRE)–Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the company’s AMBULATE series that are studying the VASCADE MVP Venous Vascular Closure System for use in the closure of mid-bore (6-12 Fr inner diameter sheath) venous access sites.

AMBULATE is a randomized, multi-center study evaluating the VASCADE MVP System compared to manual compression for multi-access, catheter-based procedures such as cardiac ablation for atrial fibrillation. The goal of the trial is to demonstrate significantly reduced time-to-ambulation for patients following these common and high-growth electrophysiology procedures.

Twenty-nine physicians enrolled 204 patients in the AMBULATE pivotal trial at 13 sites across the United States. Principal investigators include Dr. Andrea Natale, executive medical director, Texas Cardiac Arrhythmia Institute; Dr. Mintu Turakhia, associate professor, Stanford University School of Medicine; and Dr. Steve Compton, Alaska Heart and Vascular Institute.

“Cardiac ablation is a very successful procedure for treating atrial fibrillation. However, patients frequently suffer back pain from the extended bed rest required and pain at the venous access sites due to manual compression,” said Dr. Natale. “With the AMBULATE trial our objective is to demonstrate the ability of the VASCADE MVP system to provide a substantial reduction in bed rest time and eliminate the need for manual compression following an ablation procedure.”

“The AMBULATE pivotal trial fully enrolled in less than six months, which is a testament to the study’s outstanding investigators and their research teams – and to the appeal of the VASCADE MVP System for their patients,” said John Russell, CEO of Cardiva Medical. “AMBULATE is the first trial of its kind in this category, and may point the way to better patient satisfaction and lower costs for these procedures.”

The AMBULATE Series of Clinical Studies

Additional studies in the industry-leading AMBULATE series include:

• AMBULATE IMPACT Study – a recently completed study that examines today’s workflow following ablation procedures with a focus on improving hospital economics through early patient ambulation. Data from AMBULATE IMPACT will be presented during a Satellite Symposium at the annual Heart Rhythm Scientific Sessions 2018 on May 10 in Boston.
• AMBULATE CE Study – a single-arm study of the VASCADE MVP System that was submitted to support the pending CE Mark in the European Union. Forty patients were enrolled by 11 physicians at five sites.

• AMBULATE CAP Study – a continued access protocol study designed to evaluate the VASCADE MVP System for enabling earlier hospital discharge and other endpoints in the setting of electrophysiology procedures. The AMBULATE CAP protocol is under review by the U.S. Food and Drug Administration (FDA).

Heart Rhythm 2018

Cardiva will also have a presence at Heart Rhythm 2018, the Heart Rhythm Society’s Scientific Sessions, being held in Boston from May 9-12. Company activities include:

• Satellite Symposium: “Early Ambulation for AF Ablation Patients – Opportunities, Challenges, Economics. Results of the AMBULATE IMPACT Study”. The symposium will be held from 6:30-8:30 p.m. on Thursday, May 10 and will feature a world-class faculty including Andrea Natale, M.D., Suneet Mittal, M.D., Amin Al-Ahmad, M.D. and Mintu Turakhia, M.D. Visit here for more information and to register to attend: 
• Booth #774. Representatives will be available to discuss the VASCADE Vascular Closure System, which recently received FDA approval for 5-7 Fr femoral vein closure in addition to femoral arterial closure. Information will also be available about all of the AMBULATE studies.

About the VASCADE Vascular Closure Systems

VASCADE is a fully integrated, extravascular, bioabsorbable femoral access closure system that is easy to use, leaves no permanent components behind, and has demonstrated safety and efficacy in a wide range of patients. The system combines Cardiva’s proven proprietary collapsible disc technology and a thrombogenic resorbable collagen patch in an integrated design. For patients and healthcare providers, VASCADE enables secure and rapid hemostasis while minimizing complications, including bleeding at the access site.

VASCADE works by placing a small, collapsible mesh disc against the inside of the vessel wall to temporarily stop the bleeding, releasing a collagen patch into the tissue and then removing the mesh disc. The collagen patch expands, providing a mechanical and physiological seal to stop the bleeding, and then absorbs into the body, leaving nothing behind and allowing further access to the vessel if additional procedures are required.

The VASCADE MVP System is a new, investigational device built upon the established and clinically proven VASCADE system.

About Cardiva Medical, Inc.

Cardiva Medical, Inc. is a privately held medical device company focused on developing and commercializing innovative vascular closure technologies. The Company is headquartered in Santa Clara, Calif. For further information, visit our website at www.cardivamedical.com and follow us on Twitter at @CardivaMedical.

VASCADE® and Cardiva Catalyst® are registered trademarks of Cardiva Medical^®, Inc.